WO1996019234A1 - Mobilisation of haematopoietic cells - Google Patents
Mobilisation of haematopoietic cells Download PDFInfo
- Publication number
- WO1996019234A1 WO1996019234A1 PCT/GB1995/002929 GB9502929W WO9619234A1 WO 1996019234 A1 WO1996019234 A1 WO 1996019234A1 GB 9502929 W GB9502929 W GB 9502929W WO 9619234 A1 WO9619234 A1 WO 9619234A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- csf
- cells
- cxc chemokine
- hpa
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2053—IL-8
Definitions
- This invention relates to the combined use of CxC chemokines and haematopoiesis priming agents such as colony stimulating factors (CSFs), to promote the release and mobilisation of haematopoietic cells from the marrow.
- CSFs colony stimulating factors
- Such agents are useful in treatments where the enrichment of blood with haematopoietic stem cells and mature cells would be of value, for example in peripheral blood stem cell transplantation (PBSCT) and in enhancing immune responses.
- PBSCT peripheral blood stem cell transplantation
- haematopoietic stem cells which are both pluripotent - that is they can give rise to all blood cell types, such as leukocytes and erythrocytes - and capable of self-renewal.
- Leukopaenia or depletion from the blood system of these leukocytes renders an individual susceptible to infection. This leukopaenia can occur during some viral infections, but clinically the most important cause is chemotherapy or radiotherapy used to treat malignant disease.
- stem cells and progenitor cells must be mobilised from the bone marrow. Following mobilisation, these stem cells must be collected and concentrated by apheresis procedures, before transplantation.
- G-CSF granulocyte-CSF
- GM-CSF granulocyte-macrophage-CSF
- GM-CSF + chemotherapy Haas et al. (1992) Bone Marrow Transplantation. 9:459-465; Campos et al. (1993) Leukemia. 9(7):1409-1415
- GM-CSF + IL-3 Emerson et al. (1988) J. Clin. Invest. 82:1282-1287; Kanz et al. (1993) Eur. J. Cancer. 29A (Suppl 5) pp. s23-s26)
- GM-CSF/IL-3 fusion protein (PIXY321) (Curtis et al. (1991 ) Proc. Natl. Acad. Sci. U.S.A. 88:5809-5813.
- SCF Stem cell factor
- GM-CSF GM-CSF
- IL-3 multi-CSF
- colony stimulating factors such as high dose cyclophosphamide, Ara-C and 5-fluorouracil
- cytotoxic drugs such as high dose cyclophosphamide, Ara-C and 5-fluorouracil, are known to prime the differentiation and expansion of haematopoietic stem and progenitor cells to mature blood cells and their eventual release from the bone marrow into the circulating blood system.
- This invention is based on the discovery that members of the CxC chemokine sub ⁇ family can act in synergy with colony stimulating factors to promote the mobilisation of stem cells and mature haematopoietic cells to circulating blood, resulting in an increase of circulating stem cells and mature blood cell types, such as neutrophils and monocytes.
- the levels of stem cell mobilisation and increased mature blood cell concentrations obtained are greater with the combined administration of a CSFs and a CxC chemokine, than by treatment with either of the individual components.
- G-CSF- or GM-CSF-induced release of stem cells from the bone marrow is slow, unpredictable and occurs over a long period of time, taking for example between 4 and 14 days.
- prolonged administration of a CSF can lead to undesirable side effects such asi ⁇ ter alia bone pain and fever, and successful engraftment can require multiple apheresis procedures to accumulate sufficient haematopoietic stem cells to ensure re-population.
- the timing of the apheresis and the stem cell yield are variable.
- haematopoietic stem cell mobilisation and increased mature blood cell concentrations in the blood stream achievable by haematopoietic priming agents such as colony stimulating factors, can be increased rapidly by administration of a CxC chemokine, and the time course of stem cell and mature blood cell release is highly predictable.
- the invention therefore has application inter alia in the treatment of cancer patients undergoing chemotherapy, in the treatment of patients with acute leukopaenia and in patients suffering from the effects of acute infection.
- CxC chemokines such as IL-8, NAP-1 and GRO-aipha are in themselves known.
- Haematopoietic priming agents such as cytotoxic chemical compounds, anti-VLA 4 antibodies (Papayannopoulou and Nakamoto, ibid) and colony stimulating factors for example G-CSF, GM-CSF, are also known.
- treatment with both a CxC and a haematopoiesis priming agent to achieve haematopoietic stem and progenitor cell mobilisation or to achieve increases in the number of mature blood cells does not appear to have been proposed previously.
- This invention follows from the surprising discovery that members of the CxC chemokine sub-family, can act in synergy with a haematopoiesis priming agent (HPA) for the mobilisation of haematopoietic stem cells and for increasing the mature blood cell concentrations, predominantly of neutrophils, monocytes and basophils.
- HPA haematopoiesis priming agent
- a CxC chemokine and a haematopoiesis priming agent in the preparation of an agent for promoting the release and mobilisation of haematopoietic cells into the bloodstream.
- the invention is thus useful in a method for inducing the release of haematopoietic stem cells from the marrow of an animal, and for increasing the concentration of mature haematopoietic blood cell subsets, the method comprising the simultaneous, sequential or individual administration to an animal, of an effective dose of a HPA and a CxC chemokine.
- Haematopoietic cells include stem cells, progenitor cells and differentiated cells of the haematopoietic system including platelets, erythrocytes and leukocytes (white blood cells), which include inter alia neutrophils, basophils, monocytes and lymphocytes.
- haematopoiesis priming agent refers to any agent capable of mobilising haematopoietic stem cells or progenitor cells or leukocytes into the bloodstream.
- HPAs include but are not limited to colony stimulating factors (CSF), cytotoxic chemical compounds (for example cyclophosphamide, Ara C or 5-fluorouracil) and anti-VL- antibodies.
- a HPA acts to prime the marrow by shifting the stem cells and progenitor cells out of their quiescent steady state, thereby allowing the CxC chemokine to rapidly mobilise the haematopoietic cells into the bloodstream.
- colony stimulating factor or "CSF as used throughout the specification refers to cytokines which induce progenitor cells found in the bone marrow to differentiate into mature blood cell types.
- Colony stimulating factors which find use in the invention include, but are not limited to: neutrophil granulocyte CSF (G-CSF), granulocyte-macrophage CSF (GM-CSF), macrophage CSF (M.-CSF, CSF-1 ) , multi-CSF (IL-3), erythropoietin (EPO), eosinophil CSF (Eos-CSF, IL-5), stem cell factor (SCF), erythroid potentiating activity (EPA), interleukin-7 (IL-7), interleukin-11 (IL-11 ) and interleukin-12 (IL-12), or functional variants thereof.
- G-CSF neutrophil granulocyte CSF
- GM-CSF granulocyte-macrophage CSF
- M.-CSF, CSF-1 macrophage CSF
- IL-3 multi-CSF
- EPO erythropoietin
- Eos-CSF eosinophil CSF
- cytokine which has the attributes of affecting differentiation or proliferation of haematopoietic stem and progenitor cells have utility in this invention.
- the haematopoiesis priming agent for use in the invention is a colony stimulating factor.
- the CSF for use in the invention is G- CSF, or variants thereof.
- the invention encompasses the use of naturally occurring, or recombinant CSFs, including murine and human, or protein engineered forms ("variants” and “analogues”) which may have improved biophysical or biological properties.
- Variants or analogues with improved biophysical properties include those recombinant proteins capable of being more easily expressed or purified. Variants may also possess less toxicity when administered to the patient.
- CxC chemokines refers to a family of cytokines classified in the CxC sub-family of chemokines by amino acid homology and in possessing an amino acid separating the first two cysteine groups.
- CxC chemokine protein can be used in synergy with CSFs to induce the release of haematopoietic cells.
- the invention encompasses the use of the various naturally occurring, or recombinant CxC chemokine proteins that have been described, including murine or human, as well as protein engineered forms which may have improved biophysical or biological properties ("variants” and "analogues").
- Variants or analogues with improved biophysical properties include those recombinant proteins capable of being more easily expressed or purified. Variants may also possess less toxicity when administered to the patient.
- CxC chemokines which find use in the invention include inter alia: IL-8, GRO- ⁇ , GRO- ⁇ , GRO- ⁇ , neutrophil-activating protein 2 (NAP-2), epithelial-cell-derived neutrophil- activating protein (ENA 78), platelet factor (PF4), ⁇ lP-10 and granulocyte chemotactic protein 2 (GCP-2), or functional variants thereof.
- the CxC chemokines for use in the invention are IL-8 and GRO-alpha, or functional variants thereof.
- variant (or its synonym for present purposes “analogue”) is used, broadly, in a functional sense. As a practical matter though, most variants will have a high degree of homology with the prototype molecule if biological activity is to be substantially preserved. It will be realised that the nature of changes from the prototype molecule is more important than the number of them.
- nucleic acid coding for an analogue may for example hybridise under stringent conditions (such as at approximately 35°C to 65°C in a salt solution of approximately 0.9 molar) to nucleic acid coding for the prototype molecule, or would do so but for the degeneracy of the genetic code.
- CSFs or CxC chemokines can be purified from media conditioned by particular cell types, or expressed by recombinant organisms or cells. Methods for expression and purification of CSFs or CxCs by recombinant techniques are known in the art.
- CxC chemokines and HPAs in particular CSFs which are defined as above and which are yet to be identified, also find utility in the invention.
- IL-8 and G- CSF in the preparation of an agent for promoting the release and mobilisation of haematopoietic stem, progenitor and mature blood cells into the bloodstream.
- GRO- alpha and G-CSF in the preparation of an agent for promoting the release and mobilisation of haematopoietic stem, progenitor and mature blood cells into the bloodstream.
- the invention is useful in inducing the release, into the bloodstream, of haematopoietic stem cells and committed progenitor cells, and in increasing the concentration in the blood of mature blood cells.
- Mature blood cells include neutrophils, eosinophils, basophils, monocytes, leukocytes, macrophages, lymphocytes, platelets and erythrocytes.
- the increase in the circulating number of mature blood cells may be particularly useful in potentiating the body's response to infection and tumours.
- the invention also has a clear clinical indication as an adjunct to the use of CSFs in peripheral blood cell transplantation.
- G-CSF is licensed for clinical use to promote accelerated granulocyte recovery following chemotherapy and to release stem cells from marrow so that they can be harvested before chemotherapy.
- This G-CSF induced stem cell release and expansion treatment can take between 4-14 days.
- GM-CSF is licensed for use in conjunction with autologous bone marrow transplantation. Clinical trials with other CSFs are underway
- Current G-CSF treatment generally takes 4 to 7 days, but can take up to 14 days.
- Mobilisation of stem ceils and progenitor stem cells from the marrow and increased blood concentrations of the various leukophils occurs more rapidly when CxC chemokines synergise with CSFs, producing a predictable, fast and enhanced yield of haematopoietic cells, potentially obviating the need for repeated leukapheresis.
- a CxC chemokine and a haematopoiesis priming agent in the preparation of an agent for promoting the release and mobilisation of haematopoietic stem and progenitor cells and/or for increasing the concentration in the blood of mature blood cells, prior to harvesting for peripheral blood stem cell transplantation, or peripheral blood mature cell transplantation.
- a CxC chemokine and a colony stimulating factor (CSF) in the preparation, of an agent for promoting the release and mobilisation of haematopoietic stem and progenitor cells and/or for increasing the concentration in the blood of mature blood cells, prior to harvesting for peripheral blood stem cell and/or mature cell transplantation.
- Haematopoietic stem ceils and/or mature blood cells so harvested may then be returned to the subject from whom they were removed either in whole blood, or by concentration by leukapheresis and apheresis procedures, following myeloablative treatment, e.g. chemotherapy.
- Engraftment of stem cells in this way may also be applicable for gene therapy.
- the ability of multipotent haematopoietic stem cells for self-renewal, the ability to genetically manipulate cells and tissues generally, and the ability of circulating stem cells to permeate tissues, re-enter and lodge in the bone marrow makes the self- populating haematopoietic stem cells useful targets for gene therapy.
- the synergistic use of a HPA (e.g. a CSF) and a CxC chemokine expands the number of harvestable stem cells available for gene therapy.
- haematopoietic stem ceils harvested following their mobilisation from bone marrow into the blood by the synergistic action of a CxC chemokine and a HPA.
- the harvested haematopoietic stem cells may be purified and enriched by apheresis or leukapheresis prior to genetic manipulation, and may then also be subjected to ex vivo expansion.
- haematopoietic stem cells harvested following their mobilisation from bone marrow into the blood by the synergistic action of a CxC chemokine and a CSF.
- the harvested haematopoietic stem cells may be purified and enriched by apheresis and/or leukapheresis prior to genetic manipulation, and may then also be subjected to ex vivo expansion.
- the invention for the administration to a patient, of these genetically manipulated haematopoietic stem cells to achieve long term engraftment.
- the invention also has use in preventing or treating leukopaenia, particularly neutropenia.
- neutropenia may arise as a result of microbial (such as bacterial) infection; the neutropenia can be addressed by inducing neutrophilia.
- microbial such as bacterial
- Other diseases of which neutropenia is a symptom or cause may also be treated by means of the invention, possibly in conjunction with cytotoxic agents.
- diseases are exemplified by, but not limited to, the following:
- leukophiiia The ability to induce leukophiiia will find clinical and veterinary application in all utilities where the raising of haematopoietic cell levels is important. For example, to enhance immune responses against acute or chronic infections, particularly parasitic and bacterial infections, for example in severe chronic neutropenia. It may also have a role in promoting wound healing.
- Dosage of the agent (HPA and CxC) in accordance with any aspect of the invention will be such as to be effective and will be under the control of the physician or clinician.
- doses may be in the range of from 0.001 to 1 mg/kg, preferably from 0.01 to 0.2 mg/kg.
- Doses may be administered repeatedly, for example from 1 to 6 times per day, preferably from 1 to 3 times per day. It may be preferable to administer the colony stimulating factor HPA daily for between 1 and 14 days prior to administering the CxC chemokine. Within minutes or 1 - 3 hours after administration of the CxC chemokine it may be appropriate for a unit of blood to be taken and stored, or apheresis or leukapheresis procedures carried out.
- Therapeutic or prophylactic administration of the agent can be by injection, preferably via intra-venous, intra-peritoneal, intra-muscular or sub-cutaneous routes in a clinically acceptable formulation.
- Other routes such as transdermal, oral, intranasal or by inhalation may also be possible.
- G-CSF is currently in clinical use. Therefore, identical or similar administration and formulation as that used for G-CSF can also be used for administration and/or formulation of the agent of this invention.
- FIGURE 1 is a histogram showing the leukophilic effect in mice, of IL-8 and rhGRO following initial G-CSF treatment, measured as total white blood cell (WBC) count.
- FIGURE 2 is a histogram showing the effect in mice, of IL-8 and rhGRO on neutrophil count following initial G-CSF treatment.
- FIGURE 3 is a histogram showing the effect in mice, of IL-8 and rhGRO on lymphocyte count following initial G-CSF treatment.
- FIGURE 4 is a histogram showing the effect in mice, of IL-8 and rhGRO on monocyte count following initial G-CSF treatment.
- FIGURE 5 is a histogram showing the effect in mice, of IL-8 and rhGRO on basophil count following initial G-CSF treatment.
- FIGURE 5 is a histogram showing the effect in mice, of IL-8 and rhGRO on eosinophil count following initial G-CSF treatment.
- FIGURE 7 is a histogram showing the effect of IL-8 and rhGRO on total white blood cell count in naive and G-CSF primed mice.
- FIGURE 8 is a histogram showing the effect of IL-8 and rhGRO on neutrophil count in naive and G-CSF primed mice.
- FIGURE 9 is a histogram showing the effect of IL-8 and rhGRO on lymphocyte count in naive and G-CSF primed mice.
- FIGURE 10 is a histogram showing the effect of IL-8 and rhGRO on monocyte count in naive and G-CSF primed mice.
- FIGURE 11 is a histogram showing the effect of IL-8 and rhGRO on eosinophil count in naive and G-CSF primed mice.
- FIGURE 12 is a histogram showing the effect of IL-8 and rhGRO on basophil count in naive and G-CSF primed mice.
- FIGURE 12 is a histogram showing the effect of IL-8 on haematopoietic progenitor mobilisation in G-CSF primed mice.
- FIGURE 14 is a histogram showing the effect of rhGRO on haematopoietic progenitor mobilisation in G-CSF primed mice. 1 4
- test compounds were used diluted in phosphate buffered saline (PBS; Gibco Dulbecco's 'B') for administration:
- G-CSF (neupogen, Amgen/Roche) lot No. B0343 MFD. 02 93. exp. 02 95.
- EXAMPLE 1 Mature blood cell mobilisation in response to selected chemokines. in mice primed with G-CSF.
- mice were terminally anaesthetised with halothane and blood (0.5ml) was withdrawn by cardiac puncture using a 21 G needle and 2.0ml syringe. Blood samples were immediately anticoagulated with EDTA, present in 0.5ml sample cups (Teklab, UK). Total and differentiated white blood cell counts were performed using a Technicon H1 (Bayer, UK) according to the manufacturers instructions, with FDA approved software (see Figures 1 - 6).
- PBS phosphate buffered saline
- IL-8 IL-8
- mice were terminally anaesthetised with halothane and blood (0.5ml) was withdrawn by cardiac puncture using a 21 G needle and 2.0ml syringe. Blood samples were immediately anticoagulated with EDTA, present in 0.5ml sample cups (Teklab, UK). Total and differentiated white blood cell counts were performed using a technicon H1 (Bayer.UK) according to the manufacturers instructions, with FDA approved software (See Figures 7 - 12).
- groups received PBS 40 ⁇ l s.c, or IL-8, 100 ⁇ g kg s.c. Blood was removed 30 minutes later by cardiac puncture from mice under terminal halothane anaesthesia. Blood samples were immediately pooled and anticoagulated with heparin (Multiparin, 5,000 units/ml) 100 - 200units per ml blood. Low density mononuclear cells were prepared over ficoll gradients.
- the number of haematopoietic progenitors in each sample was estimated by plating the low density mononuclear cells in methyicellulose plates containing appropriate nutrients and growth factors (commercially available from Stem Cell Technologies, Vancouver, Canada). The plates were incubated at 37°C in 5% O2, 5% CO 2 for 7 days and the colonies were scored using a low magnification microscope. The number of progenitors mobilised into the peripheral blood is presented in colony forming units (CFU) per ml .
- CFU colony forming units
- IL-8 improves the yield of peripheral blood progenitors after 3 days of G-CSF priming with an approximate 3.5-fold increases over the G-CSF treatment alone.
- the number of haematopoietic progenitors in each sample was estimated by plating the low density mononuclear cells in methylcellulose plates containing appropriate nutrients and growth factors (commercially available from Stem Cell Technologies, Vancouver, Canada). The plates were incubated at 37°C in 5% O2, 5% CO2 for 7 days and the colonies were scored using a low magnification microscope. The number of progenitors mobilised into the peripheral blood is presented in colony forming units (CFU) per ml .
- CFU colony forming units
- GRO-alpha improves the yield of peripheral blood progenitors after 3 days of G-CSF priming with an approximate 3.5- fold increases over the G-CSF treatment alone.
- haematopoiesis priming agents such as cytotoxic chemical agents, anti-VLA-j antibodies or other colony stimulating factors, such as GM-CSF, IL-3, SCF; and other CxC chemokines, such as GRO-beta , GRO-gamma, neutrophii-activating protein 2 (NAP-2), epithelial-cell-derived neutrophii-activating protein (ENA 78), platelet factor (PF4), ⁇ lP-10 and granulocyte chemotactic protein 2 (GCP-2) would be expected.
- haematopoiesis priming agents such as cytotoxic chemical agents, anti-VLA-j antibodies or other colony stimulating factors, such as GM-CSF, IL-3, SCF; and other CxC chemokines, such as GRO-beta , GRO-gamma, neutrophii-activating protein 2 (NAP-2), epithelial-cell-derived neutrophii-activating protein (ENA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95940384A EP0800402A1 (en) | 1994-12-22 | 1995-12-15 | Mobilisation of haematopoietic cells |
AU41852/96A AU4185296A (en) | 1994-12-22 | 1995-12-15 | Mobilisation of haematopoietic cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9426012A GB9426012D0 (en) | 1994-12-22 | 1994-12-22 | Mobilisation of haematopoietic cells |
GB9426012.2 | 1994-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996019234A1 true WO1996019234A1 (en) | 1996-06-27 |
Family
ID=10766443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1995/002929 WO1996019234A1 (en) | 1994-12-22 | 1995-12-15 | Mobilisation of haematopoietic cells |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0800402A1 (en) |
AU (1) | AU4185296A (en) |
GB (1) | GB9426012D0 (en) |
WO (1) | WO1996019234A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997006817A1 (en) * | 1995-08-19 | 1997-02-27 | British Biotech Pharmaceuticals Limited | Haematopoietic recovery |
EP0848012A1 (en) * | 1996-12-13 | 1998-06-17 | Roche Diagnostics GmbH | Use of polypeptides for treating thrombocytopenias |
EP0866806A1 (en) * | 1995-10-24 | 1998-09-30 | Smithkline Beecham Corporation | Method of mobilizing hematopoietic stem cells |
EP0979306A1 (en) * | 1997-02-14 | 2000-02-16 | George Washington University | An assay for the measurement of dna synthesis rates |
US6080398A (en) * | 1993-06-08 | 2000-06-27 | Smithkline Beecham Corporation | Truncated gro and KC chemokines having enhanced bioactivity |
US6447766B1 (en) | 1993-06-08 | 2002-09-10 | Smithkline Beecham Corporation | Method of mobilizing hematopoietic stem cells |
CN111778212A (en) * | 2020-07-08 | 2020-10-16 | 因诺伟(北京)生物医疗科技有限公司 | Preparation method and application of mobilized hematopoietic stem cell plasma exosome |
CN115429870A (en) * | 2022-10-12 | 2022-12-06 | 广州医科大学 | Application of interleukin 40 in preventing and treating neutropenia |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991007988A1 (en) * | 1989-12-01 | 1991-06-13 | Amgen Inc. | Megakaryocyte production |
WO1992001039A1 (en) * | 1990-07-13 | 1992-01-23 | Dana-Farber Cancer Institute, Inc. | Promotion of maturation of hematopoietic progenitor cells |
WO1994028916A1 (en) * | 1993-06-15 | 1994-12-22 | British Biotech Pharmaceuticals Limited | Release and mobilisation of haematopoietic cells |
-
1994
- 1994-12-22 GB GB9426012A patent/GB9426012D0/en active Pending
-
1995
- 1995-12-15 EP EP95940384A patent/EP0800402A1/en not_active Withdrawn
- 1995-12-15 WO PCT/GB1995/002929 patent/WO1996019234A1/en not_active Application Discontinuation
- 1995-12-15 AU AU41852/96A patent/AU4185296A/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991007988A1 (en) * | 1989-12-01 | 1991-06-13 | Amgen Inc. | Megakaryocyte production |
WO1992001039A1 (en) * | 1990-07-13 | 1992-01-23 | Dana-Farber Cancer Institute, Inc. | Promotion of maturation of hematopoietic progenitor cells |
WO1994028916A1 (en) * | 1993-06-15 | 1994-12-22 | British Biotech Pharmaceuticals Limited | Release and mobilisation of haematopoietic cells |
Non-Patent Citations (4)
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6080398A (en) * | 1993-06-08 | 2000-06-27 | Smithkline Beecham Corporation | Truncated gro and KC chemokines having enhanced bioactivity |
US6447766B1 (en) | 1993-06-08 | 2002-09-10 | Smithkline Beecham Corporation | Method of mobilizing hematopoietic stem cells |
US6399053B1 (en) | 1993-06-08 | 2002-06-04 | Smithkline Beecham Corporation | Methods of enhancing bioactivity of chemokines |
WO1997006817A1 (en) * | 1995-08-19 | 1997-02-27 | British Biotech Pharmaceuticals Limited | Haematopoietic recovery |
EP0866806A1 (en) * | 1995-10-24 | 1998-09-30 | Smithkline Beecham Corporation | Method of mobilizing hematopoietic stem cells |
EP0866806A4 (en) * | 1995-10-24 | 2002-01-09 | Smithkline Beecham Corp | Method of mobilizing hematopoietic stem cells |
WO1998025966A1 (en) * | 1996-12-13 | 1998-06-18 | Roche Diagnostics Gmbh | Use of polypeptides for treating thrombocytopenia |
US6403553B1 (en) | 1996-12-13 | 2002-06-11 | Wolf-Georg Forssmann | Use of polypeptides for treating thrombocytopenia |
EP0848012A1 (en) * | 1996-12-13 | 1998-06-17 | Roche Diagnostics GmbH | Use of polypeptides for treating thrombocytopenias |
EP0979306A1 (en) * | 1997-02-14 | 2000-02-16 | George Washington University | An assay for the measurement of dna synthesis rates |
EP0979306A4 (en) * | 1997-02-14 | 2004-09-01 | Univ George Washington | An assay for the measurement of dna synthesis rates |
CN111778212A (en) * | 2020-07-08 | 2020-10-16 | 因诺伟(北京)生物医疗科技有限公司 | Preparation method and application of mobilized hematopoietic stem cell plasma exosome |
CN111778212B (en) * | 2020-07-08 | 2022-09-27 | 因诺伟(北京)生物医疗科技有限公司 | Preparation method and application of mobilized hematopoietic stem cell plasma exosome |
CN115429870A (en) * | 2022-10-12 | 2022-12-06 | 广州医科大学 | Application of interleukin 40 in preventing and treating neutropenia |
CN115429870B (en) * | 2022-10-12 | 2023-07-21 | 广州医科大学 | Application of interleukin 40 in preventing and treating neutropenia |
Also Published As
Publication number | Publication date |
---|---|
GB9426012D0 (en) | 1995-02-22 |
AU4185296A (en) | 1996-07-10 |
EP0800402A1 (en) | 1997-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7067489B2 (en) | Hematopoietic stimulation | |
US5310550A (en) | Method of treating thrombocytopenia using human BCDF in combination with IL-3 | |
US10029000B2 (en) | Uses of IL-12 in hematopoiesis | |
JPH06508613A (en) | Improved method of autografting | |
JP3058353B2 (en) | How to increase hematopoietic cells | |
WO1995009005A1 (en) | Methods for stimulating interleukin-6 synthesis and inducing thrombocytopoiesis using oncostatin m | |
JP5989727B2 (en) | Use of IL-12 in hematopoiesis | |
WO1996019234A1 (en) | Mobilisation of haematopoietic cells | |
JPH0276820A (en) | Agent for supporting transplantation treatment of bone marrow | |
Winton et al. | Effect of recombinant human interleukin-6 (rhIL-6) and rhIL-3 on hematopoietic regeneration as demonstrated in a nonhuman primate chemotherapy model | |
JPH11512747A (en) | How to recruit hematopoietic stem cells | |
WO1991014424A1 (en) | Methods for protecting against chemotherapy-induced hair loss | |
Neta et al. | Utility of interleukin-1 in therapy of radiation injury as studied in small and large animal models | |
Smith | Use of hematopoietic growth factors for treatment of aplastic anemia | |
JP2008500948A6 (en) | Use of IL-12 in hematopoiesis | |
EP0661057A1 (en) | Hematopoietic cell proliferation accelerator | |
Thatcher | New perspectives in lung cancer. 4. Haematopoietic growth factors and lung cancer treatment. | |
WO1997006817A1 (en) | Haematopoietic recovery | |
Chovanec | Effects of Uteroferrin on Hematopoietic Parameters in Normal Pigs | |
JP2001516341A (en) | Hematopoietic cell enhancement | |
Rosenthal et al. | Growth Factors in Myelodysplastic Syndromes | |
WO1998031385A9 (en) | Enhancement of hematopoietic cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN CZ DE FI GB HU JP KR NO NZ PL RU SK UA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1997 860068 Date of ref document: 19970620 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995940384 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1995940384 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995940384 Country of ref document: EP |